Theravance Inc. will pay GlaxoSmithKline $15 million for winning European approval of the lung disease treatment Relvar Ellipta and will pay out another $15 million when GSK launches the drug ...
LONDON, Sept 19 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been recommended for approval in Europe, Britain's biggest drugmaker said on Thursday. The green light ...
LONDON (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Europe to treat both asthma and chronic obstructive pulmonary disease (COPD), confirming an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results